Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
Audrey Le Floc’h, Jeanne Allinne, Kirsten Nagashima, et al.
Allergy (2019) Vol. 75, Iss. 5, pp. 1188-1204
Open Access | Times Cited: 328

Showing 1-25 of 328 citing articles:

Type 2 immunity in the skin and lungs
Cezmi A. Akdiş, Peter D. Arkwright, Marie‐Charlotte Brüggen, et al.
Allergy (2020) Vol. 75, Iss. 7, pp. 1582-1605
Open Access | Times Cited: 419
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
Evan S. Dellon, Marc E. Rothenberg, Margaret H. Collins, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 25, pp. 2317-2330
Open Access | Times Cited: 283
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 3, pp. 205-214
Open Access | Times Cited: 227
EAACI Biologicals Guidelines—Recommendations for severe asthma
Ioana Agache, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Allergy (2020) Vol. 76, Iss. 1, pp. 14-44
Open Access | Times Cited: 217
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
Michael E. Wechsler, Linda B. Ford, Jorge Máspero, et al.
The Lancet Respiratory Medicine (2021) Vol. 10, Iss. 1, pp. 11-25
Open Access | Times Cited: 164
Type 2 inflammation in asthma and other airway diseases
Jorge Máspero, Yochai Adir, Mona Al‐Ahmad, et al.
ERJ Open Research (2022) Vol. 8, Iss. 3, pp. 00576-2021
Open Access | Times Cited: 154
Biologics and airway remodeling in severe asthma
Gilda Varricchi, Sebastian Ferri, J. Pepys, et al.
Allergy (2022) Vol. 77, Iss. 12, pp. 3538-3552
Open Access | Times Cited: 150
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis
Michael E. Wechsler, Amy D. Klion, Pierluigi Paggiaro, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 10, pp. 2695-2709
Open Access | Times Cited: 143
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis
Lisa A. Beck, Michael J. Cork, Masayuki Amagai, et al.
JID Innovations (2022) Vol. 2, Iss. 5, pp. 100131-100131
Open Access | Times Cited: 141
Mechanisms of allergen-specific immunotherapy and allergen tolerance
Umut Can Küçüksezer, Cevdet Özdemir, Lacin Cevhertas, et al.
Allergology International (2020) Vol. 69, Iss. 4, pp. 549-560
Open Access | Times Cited: 139
IL-13 is a driver of COVID-19 severity
Alexandra N. Donlan, Tara E. Sutherland, Chelsea Marie, et al.
JCI Insight (2021)
Open Access | Times Cited: 138
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Jennifer D. Hamilton, Sivan Harel, Brian N. Swanson, et al.
Clinical & Experimental Allergy (2021) Vol. 51, Iss. 7, pp. 915-931
Open Access | Times Cited: 124
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
Andrew Blauvelt, Emma Guttman‐Yassky, Amy S. Paller, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 3, pp. 365-383
Open Access | Times Cited: 79
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marc E. Rothenberg, Evan S. Dellon, Margaret H. Collins, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 11, pp. 990-1004
Closed Access | Times Cited: 49
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
Marcus Maurer, Thomas B. Casale, Sarbjit S. Saini, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 1, pp. 184-194
Open Access | Times Cited: 36
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
Mirna Chehade, Evan S. Dellon, Jonathan M. Spergel, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 24, pp. 2239-2251
Closed Access | Times Cited: 33
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma
Richard Russell, Louis‐Philippe Boulet, Christopher E. Brightling, et al.
European Respiratory Journal (2024) Vol. 63, Iss. 4, pp. 2301397-2301397
Open Access | Times Cited: 29
The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps
Claus Bachert, Alexandra Hicks, Simon Gane, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 16
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma
Tanya M. Laidlaw, Claus Bachert, Nikhil Amin, et al.
Annals of Allergy Asthma & Immunology (2021) Vol. 126, Iss. 5, pp. 584-592.e1
Open Access | Times Cited: 85
Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice
Eva Conde, Romain Bertrand, Bianca Balbino, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 83
<p>Targeting IL-4 for the Treatment of Atopic Dermatitis</p>
Andrea Chiricozzi, Martina Maurelli, Ketty Peris, et al.
ImmunoTargets and Therapy (2020) Vol. Volume 9, pp. 151-156
Open Access | Times Cited: 79
COVID-19—Lessons Learned and Questions Remaining
Ferric C. Fang, Constance A. Benson, Carlos del Rı́o, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 12, pp. 2225-2240
Open Access | Times Cited: 77
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Leonard B. Bacharier, Jorge Máspero, Constance H. Katelaris, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24, pp. 2230-2240
Open Access | Times Cited: 74
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study
Andrew Menzies‐Gow, Claire McBrien, Bindhu Unni, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 63-78
Open Access | Times Cited: 69
Page 1 - Next Page

Scroll to top